What caused the ABT.SW stock volume spike today?

The spike reflects concentrated buying and rebalancing in the SIX session, with **volume 40.00** vs avg **1.00**. Likely drivers: fund flows into Healthcare, block trades and positioning ahead of Abbott news or sector moves.

Is ABT.SW stock fairly valued versus peers?

Abbott trades at **PE 34.25**, near the Healthcare sector average **PE 34.87**. Price/sales **5.10** and price/book **4.45** show premium pricing but solid cash flow metrics support valuation.

What short-term price targets exist for ABT.SW stock?

Meyka AI's model lists a **quarterly target CHF110.78** (+**10.78%**) and a **yearly CHF91.69** (-**8.31%**). These are projections, not guarantees, and intraday moves can differ materially.

How should traders manage risk after the ABT.SW spike?

Use size limits and stops; consider stop placement near **CHF94.00** support and monitor volume profile. The spike increases intraday volatility, so prefer smaller position sizes until volume normalises.

CH Stocks

ABT.SW volume spike to CHF100.00 (SIX) 29 Jan 2026: assess upside

ByDanny Kontos January 29, 2026

A sharp intraday volume spike pushed ABT.SW stock to CHF100.00 on 29 Jan 2026, up 1.00 point or 1.01% from yesterday in the Switzerland (SIX) session. The print shows volume 40.00 vs average 1.00 (relative volume 40.00), signalling abnormal liquidity that traders should note. We examine drivers, valuation, technical setup and Meyka AI’s short-term forecasts to frame possible intraday and near-term moves for Abbott Laboratories (ABT.SW).